Intellia Therapeutics shares rallied 7.6% in the last trading session to close at $12.6, a move that appears to reflect growing investor confidence in the company's regulatory progress and financial position. The FDA accepted the biologics license application for lonvoguran ziclumeran, or lonvo-z, Intellia's investigational CRISPR-based treatment for hereditary angioedema, under Priority Review with a March 10, 2027 decision date. The company also secured an OrbiMed debt facility of up to $400 million in September, including $75 million upfront, to help support development and potential commercialization. Intellia is expected to post a quarterly loss of $0.82 per share in its upcoming report, a year-over-year change of +10.9%, on revenues of $10 million, down 27.5% from the year-ago quarter, while the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. The stock currently carries a Zacks Rank #3 (Hold).
Intellia Therapeutics IncFDA accepted the BLA for lonvo-z under Priority Review with a March 10, 2027 decision date
ADMA Biologics IncOrbiMed provided Intellia a debt facility of up to $400 million; mentioned only as the lender
